Di Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Di Yao has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Minghuan Wang
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
3 shared publications Rong Li
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publicationsJia Li
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publicationsJiahuan Hao
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publicationsMinjie Xie
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publicationsWei Wang
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications
Latest Publications
- 18 November 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (22)
Sleep‐Deprivation Serum Induces Mitochondrial Stress in BV2 Cells: Responses to P2Y12 ‐Targeted Pharmacological Modulation
Sleep deprivation (SD) disrupts neuroimmune and metabolic homeostasis, but whether circulating factors generated after sleep loss alter microglial responses to purinergic pharmacological modulation remains unclear. P2Y12 is a microglia‐enriched purinergic receptor that regulates process dynamics, calcium signaling, and microglial interactions with neurons and vascular‐glial interfaces. Here, we established an in vitro serum‐transfer model to test whether serum from sleep‐deprived mice alters mitochondrial and Rhod‐2 fluorescence responses to P2Y12‐targeted compounds in BV2 cells. Mice were subjected to forced‐wheel SD consisting of one wheel revolution every 2 s for 4 h per day over 4 consecutive days, and serum was obtained by cardiac blood collection followed by centrifugation. BV2 cells were treated with control or SD serum in the absence or presence of the P2Y12 antagonist MRS2395 or the P2Y12 agonist 2‐MeSADP. Mitochondrial membrane potential was assessed by JC‐1 red/green ratio imaging, mitochondrial network integrity by MitoTracker‐based segmentation and skeletonization, and Rhod‐2 fluorescence responses by single‐cell F / F 0 imaging. SD serum decreased the JC‐1 ratio, increased maximal depolarization, reduced mitochondrial skeleton length and mitochondrial area fraction, and suppressed Rhod‐2 responses. Under control‐serum conditions, MRS2395 markedly enhanced Rhod‐2 responses, whereas the increase in the area under the Rhod‐2 response curve with 2‐MeSADP was not significant after Holm correction. Under SD‐serum conditions, however, neither compound consistently restored the mitochondrial or Rhod‐2 response profile. Together, these findings link SD‐serum exposure to mitochondrial impairment and attenuated Rhod‐2 fluorescence responses in BV2 cells, and suggest that serum context may influence cellular responses to P2Y12‐targeted compounds.
- 18 November 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (22)
Sleep‐Deprivation Serum Induces Mitochondrial Stress in BV2 Cells: Responses to P2Y12 ‐Targeted Pharmacological Modulation
Sleep deprivation (SD) disrupts neuroimmune and metabolic homeostasis, but whether circulating factors generated after sleep loss alter microglial responses to purinergic pharmacological modulation remains unclear. P2Y12 is a microglia‐enriched purinergic receptor that regulates process dynamics, calcium signaling, and microglial interactions with neurons and vascular‐glial interfaces. Here, we established an in vitro serum‐transfer model to test whether serum from sleep‐deprived mice alters mitochondrial and Rhod‐2 fluorescence responses to P2Y12‐targeted compounds in BV2 cells. Mice were subjected to forced‐wheel SD consisting of one wheel revolution every 2 s for 4 h per day over 4 consecutive days, and serum was obtained by cardiac blood collection followed by centrifugation. BV2 cells were treated with control or SD serum in the absence or presence of the P2Y12 antagonist MRS2395 or the P2Y12 agonist 2‐MeSADP. Mitochondrial membrane potential was assessed by JC‐1 red/green ratio imaging, mitochondrial network integrity by MitoTracker‐based segmentation and skeletonization, and Rhod‐2 fluorescence responses by single‐cell F / F 0 imaging. SD serum decreased the JC‐1 ratio, increased maximal depolarization, reduced mitochondrial skeleton length and mitochondrial area fraction, and suppressed Rhod‐2 responses. Under control‐serum conditions, MRS2395 markedly enhanced Rhod‐2 responses, whereas the increase in the area under the Rhod‐2 response curve with 2‐MeSADP was not significant after Holm correction. Under SD‐serum conditions, however, neither compound consistently restored the mitochondrial or Rhod‐2 response profile. Together, these findings link SD‐serum exposure to mitochondrial impairment and attenuated Rhod‐2 fluorescence responses in BV2 cells, and suggest that serum context may influence cellular responses to P2Y12‐targeted compounds.
- Top Cited PapersOpen Access
- 6 October 2023
- Published by Springer Nature in Translational Psychiatry
- Vol. 13 (1) , 1-14
Melatonin alleviates depression-like behaviors and cognitive dysfunction in mice by regulating the circadian rhythm of AQP4 polarization
Depression is a common chronic psychiatric illness, which is resistant to medical treatments. While melatonin may alleviate certain depression symptoms, evidence for its efficacy against core symptoms is lacking. Here, we tested a mechanism whereby melatonin rescues the behavioral outcomes of the chronic unpredictable mild stress (CUMS) mouse model of depression. CUMS mice showed depressive behaviors to tail suspension, open field behavior, and sucrose preference test, and cognitive dysfunction in the Morris water maze. Impairments in these measures were relieved by melatonin treatment. Moreover, CUMS mice had impaired glymphatic function across the sleep-wake cycle due to the astrocytic loss and disturbance of circadian regulation of the polarized expression of aquaporin-4 (AQP4) water channels in perivascular astrocytes. EEG results in CUMS mice showed a reduced total sleep time and non-rapid eye movement (NREM) sleep, due to sleep fragmentation in the light phase. CUMS mice lost the normal rhythmic expressions of circadian proteins Per2, Cry2, Bmal1, Clock, and Per1. However, the melatonin treatment restored glymphatic system function and the polarization of AQP4, while improving sleep structure, and rectifying the abnormal expression of Per2, Bmal1, Clock, and Per1 in CUMS mice. Interestingly, Per2 expression correlated negatively with the polarization of AQP4. Further studies demonstrated that Per2 directed the location of AQP4 expression via interactions with the α-dystrobrevin (Dtna) subunit of AQP4 in primary cultured astrocytes. In conclusion, we report a new mechanism whereby melatonin improves depression outcomes by regulating the expression of the circadian protein Per2, maintaining the circadian rhythm of astrocytic AQP4 polarization, and restoring glymphatic function.
- 6 October 2023
- Published by Springer Nature in Translational Psychiatry
- Vol. 13 (1) , 1-14
Top Cited PapersOpen AccessMelatonin alleviates depression-like behaviors and cognitive dysfunction in mice by regulating the circadian rhythm of AQP4 polarization
Depression is a common chronic psychiatric illness, which is resistant to medical treatments. While melatonin may alleviate certain depression symptoms, evidence for its efficacy against core symptoms is lacking. Here, we tested a mechanism whereby melatonin rescues the behavioral outcomes of the chronic unpredictable mild stress (CUMS) mouse model of depression. CUMS mice showed depressive behaviors to tail suspension, open field behavior, and sucrose preference test, and cognitive dysfunction in the Morris water maze. Impairments in these measures were relieved by melatonin treatment. Moreover, CUMS mice had impaired glymphatic function across the sleep-wake cycle due to the astrocytic loss and disturbance of circadian regulation of the polarized expression of aquaporin-4 (AQP4) water channels in perivascular astrocytes. EEG results in CUMS mice showed a reduced total sleep time and non-rapid eye movement (NREM) sleep, due to sleep fragmentation in the light phase. CUMS mice lost the normal rhythmic expressions of circadian proteins Per2, Cry2, Bmal1, Clock, and Per1. However, the melatonin treatment restored glymphatic system function and the polarization of AQP4, while improving sleep structure, and rectifying the abnormal expression of Per2, Bmal1, Clock, and Per1 in CUMS mice. Interestingly, Per2 expression correlated negatively with the polarization of AQP4. Further studies demonstrated that Per2 directed the location of AQP4 expression via interactions with the α-dystrobrevin (Dtna) subunit of AQP4 in primary cultured astrocytes. In conclusion, we report a new mechanism whereby melatonin improves depression outcomes by regulating the expression of the circadian protein Per2, maintaining the circadian rhythm of astrocytic AQP4 polarization, and restoring glymphatic function.
- 14 November 2022
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 39 (3) , 503-518
Updated Understanding of the Glial-Vascular Unit in Central Nervous System Disorders
The concept of the glial-vascular unit (GVU) was raised recently to emphasize the close associations between brain cells and cerebral vessels, and their coordinated reactions to diverse neurological insults from a “glio-centric” view. GVU is a multicellular structure composed of glial cells, perivascular cells, and perivascular space. Each component is closely linked, collectively forming the GVU. The central roles of glial and perivascular cells and their multi-level interconnections in the GVU under normal conditions and in central nervous system (CNS) disorders have not been elucidated in detail. Here, we comprehensively review the intensive interactions between glial cells and perivascular cells in the niche of perivascular space, which take part in the modulation of cerebral blood flow and angiogenesis, formation of the blood-brain barrier, and clearance of neurotoxic wastes. Next, we discuss dysfunctions of the GVU in various neurological diseases, including ischemic stroke, spinal cord injury, Alzheimer’s disease, and major depression disorder. In addition, we highlight the possible therapies targeting the GVU, which may have potential clinical applications.
- 14 November 2022
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 39 (3) , 503-518
Updated Understanding of the Glial-Vascular Unit in Central Nervous System Disorders
The concept of the glial-vascular unit (GVU) was raised recently to emphasize the close associations between brain cells and cerebral vessels, and their coordinated reactions to diverse neurological insults from a “glio-centric” view. GVU is a multicellular structure composed of glial cells, perivascular cells, and perivascular space. Each component is closely linked, collectively forming the GVU. The central roles of glial and perivascular cells and their multi-level interconnections in the GVU under normal conditions and in central nervous system (CNS) disorders have not been elucidated in detail. Here, we comprehensively review the intensive interactions between glial cells and perivascular cells in the niche of perivascular space, which take part in the modulation of cerebral blood flow and angiogenesis, formation of the blood-brain barrier, and clearance of neurotoxic wastes. Next, we discuss dysfunctions of the GVU in various neurological diseases, including ischemic stroke, spinal cord injury, Alzheimer’s disease, and major depression disorder. In addition, we highlight the possible therapies targeting the GVU, which may have potential clinical applications.
- 27 October 2021
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 38 (2) , 181-199
Digoxin Ameliorates Glymphatic Transport and Cognitive Impairment in a Mouse Model of Chronic Cerebral Hypoperfusion
The glymphatic system plays a pivotal role in maintaining cerebral homeostasis. Chronic cerebral hypoperfusion, arising from small vessel disease or carotid stenosis, results in cerebrometabolic disturbances ultimately manifesting in white matter injury and cognitive dysfunction. However, whether the glymphatic system serves as a potential therapeutic target for white matter injury and cognitive decline during hypoperfusion remains unknown. Here, we established a mouse model of chronic cerebral hypoperfusion via bilateral common carotid artery stenosis. We found that the hypoperfusion model was associated with significant white matter injury and initial cognitive impairment in conjunction with impaired glymphatic system function. The glymphatic dysfunction was associated with altered cerebral perfusion and loss of aquaporin 4 polarization. Treatment of digoxin rescued changes in glymphatic transport, white matter structure, and cognitive function. Suppression of glymphatic functions by treatment with the AQP4 inhibitor TGN-020 abolished this protective effect of digoxin from hypoperfusion injury. Our research yields new insight into the relationship between hemodynamics, glymphatic transport, white matter injury, and cognitive changes after chronic cerebral hypoperfusion.
- 27 October 2021
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 38 (2) , 181-199
Digoxin Ameliorates Glymphatic Transport and Cognitive Impairment in a Mouse Model of Chronic Cerebral Hypoperfusion
The glymphatic system plays a pivotal role in maintaining cerebral homeostasis. Chronic cerebral hypoperfusion, arising from small vessel disease or carotid stenosis, results in cerebrometabolic disturbances ultimately manifesting in white matter injury and cognitive dysfunction. However, whether the glymphatic system serves as a potential therapeutic target for white matter injury and cognitive decline during hypoperfusion remains unknown. Here, we established a mouse model of chronic cerebral hypoperfusion via bilateral common carotid artery stenosis. We found that the hypoperfusion model was associated with significant white matter injury and initial cognitive impairment in conjunction with impaired glymphatic system function. The glymphatic dysfunction was associated with altered cerebral perfusion and loss of aquaporin 4 polarization. Treatment of digoxin rescued changes in glymphatic transport, white matter structure, and cognitive function. Suppression of glymphatic functions by treatment with the AQP4 inhibitor TGN-020 abolished this protective effect of digoxin from hypoperfusion injury. Our research yields new insight into the relationship between hemodynamics, glymphatic transport, white matter injury, and cognitive changes after chronic cerebral hypoperfusion.
- Open Access
- 28 April 2020
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 26 (9) , 925-939
Caspase‐1 inhibition prevents neuronal death by targeting the canonical inflammasome pathway of pyroptosis in a murine model of cerebral ischemia
Aims: The involvement of pyroptosis in ischemic stroke remains to be established. Therefore, we used the specific pyroptosis inhibitor Vx765 as an experimental intervention target in a murine model of stroke.Methods: A total of 564 C57BL/6 mice were subjected to photothrombotic procedures and treated via gavage with Vx765 at 1‐hour post‐ischemia. We subsequently assessed the expression of Gasdermin D (GSDMD), inflammasomes, caspase‐1, and interleukin‐1β (IL‐1β) using immunofluorescence (IF) and Western blot (WB) analyses. We also examined ultrastructural changes of cortical neurons with transmission electron microscopy (TEM) and measured infarct volumes dynamically by magnetic resonance imaging (MRI). Moreover, we evaluated the neurologic deficits by modified neurological severity scores, the rotarod test, and Treadscan.Results: Elevated expression of GSDMD and GSDMD p30, the pore‐forming subunit, was evident in the peri‐ischemic region on days one and three post‐ischemia. The neuronal plasma, nuclear, and mitochondrial membranes showed ultrastructural damage at day three post‐stroke. Elevated expression of inflammasomes, caspase‐1, and IL‐1β was also present on days one and three post‐injury. There were significant differences between Vx765‐treated and vehicle groups in mean infarct volumes (14.36 vs 21.52 mm3; 12.34 vs 18.56 mm3; 4.13 vs 10.06 mm3; P < .05 at day one, three, and seven post‐surgery, respectively). Mice treated with Vx765 showed better motor recovery as assessed by serial behavior tests and had better neuronal survival, which was attributable to pyroptosis inhibition, as illustrated by downregulated expression of the effector protein GSDMD, inflammasomes, caspase‐1, and IL‐1β. Besides, treatment with Vx765 preserved neuronal membrane structures after the ischemic injury.Conclusions: Pyroptosis emerges as an important pathway for neuronal death in an acute ischemic stroke. Vx765, a low molecular weight drug that has proven safe in clinical epilepsy trials, has potential therapeutic value for cerebral ischemia by targeting the canonical inflammasome pathway of pyroptosis.
- 28 April 2020
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 26 (9) , 925-939
Open AccessCaspase‐1 inhibition prevents neuronal death by targeting the canonical inflammasome pathway of pyroptosis in a murine model of cerebral ischemia
Aims: The involvement of pyroptosis in ischemic stroke remains to be established. Therefore, we used the specific pyroptosis inhibitor Vx765 as an experimental intervention target in a murine model of stroke.Methods: A total of 564 C57BL/6 mice were subjected to photothrombotic procedures and treated via gavage with Vx765 at 1‐hour post‐ischemia. We subsequently assessed the expression of Gasdermin D (GSDMD), inflammasomes, caspase‐1, and interleukin‐1β (IL‐1β) using immunofluorescence (IF) and Western blot (WB) analyses. We also examined ultrastructural changes of cortical neurons with transmission electron microscopy (TEM) and measured infarct volumes dynamically by magnetic resonance imaging (MRI). Moreover, we evaluated the neurologic deficits by modified neurological severity scores, the rotarod test, and Treadscan.Results: Elevated expression of GSDMD and GSDMD p30, the pore‐forming subunit, was evident in the peri‐ischemic region on days one and three post‐ischemia. The neuronal plasma, nuclear, and mitochondrial membranes showed ultrastructural damage at day three post‐stroke. Elevated expression of inflammasomes, caspase‐1, and IL‐1β was also present on days one and three post‐injury. There were significant differences between Vx765‐treated and vehicle groups in mean infarct volumes (14.36 vs 21.52 mm3; 12.34 vs 18.56 mm3; 4.13 vs 10.06 mm3; P < .05 at day one, three, and seven post‐surgery, respectively). Mice treated with Vx765 showed better motor recovery as assessed by serial behavior tests and had better neuronal survival, which was attributable to pyroptosis inhibition, as illustrated by downregulated expression of the effector protein GSDMD, inflammasomes, caspase‐1, and IL‐1β. Besides, treatment with Vx765 preserved neuronal membrane structures after the ischemic injury.Conclusions: Pyroptosis emerges as an important pathway for neuronal death in an acute ischemic stroke. Vx765, a low molecular weight drug that has proven safe in clinical epilepsy trials, has potential therapeutic value for cerebral ischemia by targeting the canonical inflammasome pathway of pyroptosis.